<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778696</url>
  </required_header>
  <id_info>
    <org_study_id>UKK-PASTPVC-2018</org_study_id>
    <nct_id>NCT04778696</nct_id>
  </id_info>
  <brief_title>PASO Automated Template Matching for PVC Ablation</brief_title>
  <acronym>PAsT-PVC</acronym>
  <official_title>PASO - Automated Template Matching for PVC Ablation: A Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Köln</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pacemapping is an essential tool during ablation of idiopathic PVC and VT. Automated template&#xD;
      matching has been shown to have a significant influence on PVC ablation procedures, but the&#xD;
      PASO module of CARTO3 has not been studied in a randomized trial. The Aim of this study is to&#xD;
      evaluate the additional benefit of PASO template matching on PVC ablation procedure with&#xD;
      regard to procedural parameters and outcome when compared with conventional pace mapping. A&#xD;
      total of 144 pts will be randomised in a 1:1 fashion to PVC ablation guided by conventional&#xD;
      pacemapping vs PVC ablation guided by PASO pacemapping. Patients will be follow up with&#xD;
      Holter-ECG and TTE after 3 and 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction / Rationale Premature ventricular contractions (PVC) in the otherwise healthy&#xD;
      heart are not associated with increased mortality in the absence of a short coupling interval&#xD;
      or a compromised left ventricular function and do not require treatment if asymptomatic .&#xD;
      Symptomatic idiopathic PVC or VT on the other hand can burden patients with recurring&#xD;
      palpitations, dizziness, dyspnea and possibly syncope in cases of fast VT. A reversible&#xD;
      decrease in left ventricular function as a result of a high PVC burden has been reported even&#xD;
      in patients with no underlying cardiomyopathy . Radiofrequency Ablation (RFA) is a&#xD;
      well-established method to treat idiopathic PVC and VT, and is associated with satisfying&#xD;
      long-term results. Pacemapping is an essential tool during ablation of idiopathic PVC and VT.&#xD;
      Automated template matching has been shown to have a significant influence on PVC ablation&#xD;
      procedures, but the PASO module of CARTO3 has not been studied in a randomized trial.&#xD;
&#xD;
      Aim of the study To evaluate the additional benefit of PASO template matching on PVC ablation&#xD;
      procedure with regard to procedural parameters and outcome when compared with conventional&#xD;
      pace mapping.&#xD;
&#xD;
      Hypothesis PASO guidance during PVC / VT ablation has a significant impact on outcome after&#xD;
      catheter ablation of idiopathic PVC / VT.&#xD;
&#xD;
      Study design This study is planned as a two-center trial. All patients presenting for de novo&#xD;
      ablation of idiopathic ventricular arrhythmia will be included and randomized in a 1:1&#xD;
      fashion in this open-label, two-center, randomized controlled trial.&#xD;
&#xD;
      In patients randomized to the PASO / intervention group pacemapping will be guided by&#xD;
      automated template matching of the PASO module of CARTO3.&#xD;
&#xD;
      In patients randomized to the conventional / control group conventional pacemapping will be&#xD;
      employed.&#xD;
&#xD;
      A 3D electroanatomic geometry including activation mapping will be acquired in all patients&#xD;
      using CARTO3. Sedation, catheters and monitoring during and after CA, will not differ from&#xD;
      standard clinical practice and will be the same for both groups.&#xD;
&#xD;
      Follow-up after 3 and 12 months will assess PVC burden by Holter ECG, symptoms through a&#xD;
      standardized questionnaire and LV function by TTE&#xD;
&#xD;
      Duration and study size Based on prior findings (&quot;Impact of Automated Template Matching&#xD;
      during PVC Ablation: Results from a Randomized Controlled Trial&quot; Lüker et al. ESC 2014 poster&#xD;
      presentation) 144 pts have to be randomized to detect a significant difference with respect&#xD;
      to ablation success at follow-up (alpha 0.05, power 80%).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 simple randomisation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Patients will be masked to treatment arm. Investigator performing statistical analysis and adjudicating outcomes will be masked to treatment arm</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PVC recurrence in Holter ECG</measure>
    <time_frame>12 weeks after ablation procedure</time_frame>
    <description>Assessment of PVC as % of total number heart beats in a 24 hours Holter ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic recurrence</measure>
    <time_frame>between 3 and 12 months after ablation</time_frame>
    <description>recurrence of PVC according to the patients symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV ejection fraction assessment (%)</measure>
    <time_frame>between 3 months and 12 months after ablation</time_frame>
    <description>Change in LV ejection fraction after ablation (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>From groin puncture to sheath removal</time_frame>
    <description>Procedure duration (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prcedural fluoroscopy parameters</measure>
    <time_frame>From groin puncture to sheath removal</time_frame>
    <description>Fluoroscopy dose (Gy x cm2) and time (min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural ablation parameters</measure>
    <time_frame>From groin puncture to sheath removal</time_frame>
    <description>Number of RF lesions (n) and acute ablation success (cessation of PVC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>PVC - Premature Ventricular Complex</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Heart Failure</condition>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>conventional pace mapping</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional PVC pace mapping without visual guidance of PASO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PASO pace mapping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PASO pace mapping with visualisation in CARTO3</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PASO Pacemapping</intervention_name>
    <description>Using the PASO pacemapping visualisation module of CARTO3</description>
    <arm_group_label>PASO pace mapping</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Pacemapping</intervention_name>
    <description>without visualisation in 3D mapping</description>
    <arm_group_label>conventional pace mapping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Informed, written consent&#xD;
&#xD;
          -  ventricular arrhythmia (PVC or VT) with indication for CA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under guardianship or with mental disorders / disabilities&#xD;
&#xD;
          -  Polymorphic PVC / VT&#xD;
&#xD;
          -  ongoing myocardial ischaemia&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  valve replacement that prevents access to the suspected site of PVC origin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakob Lüker, MD</last_name>
      <phone>+4922147832396</phone>
      <email>jakob.lueker@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Jakob Lüker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Steven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

